CalciMedica Inc. Common Stock CALC · Stock Open CalciMedica Inc. Common Stock in new tab
CalciMedica Inc. Common Stock Analysis (CALC)
Is CalciMedica Inc. Common Stock a good investment? CalciMedica Inc. Common Stock (CALC) is currently trading at 1.65 USD. Market analysts have a consensus price target of 50.00 USD. This suggests a potential upside from current levels.
Earnings Schedule: CalciMedica Inc. Common Stock is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is -1.63.
Investor FAQ
Does CalciMedica Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is CalciMedica Inc. Common Stock?
CalciMedica Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -6.58.
Company Profile
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.
| Split Date | Split Ratio to 1 |
|---|---|
| March 20, 2023 | 0.07 |
| Aug. 31, 2026 | 1:5 |
Community Discussion